Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature

Koca, Emre; Kuzan, Taha Yusuf; Babacan, Taner; Türkbeyler, İbrahim Halil; Sarici, Furkan; Altundağ, Kadri̇

doi:10.1159/000357321

Cited by 14 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans, a study based on the AstraZeneca Safety Database suggested that TAM therapy of breast cancer during pregnancy is tightly associated with spontaneous abortions, fetal defects, and congenital malformations (6). To avoid significant birth defects, TAM administration needs to be discontinued during pregnancy in breast cancer patients (7)(8)(9). In rodents, adverse effects of TAM on prenatal and postnatal mice have been reported by a considerable number of studies.…”

mentioning

confidence: 99%

Single-cell RNA-seq analysis revealed long-lasting adverse effects of tamoxifen on neurogenesis in prenatal and adult brains

Lee

Zhou

Liu

et al. 2020

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

The CreER/LoxP system is widely accepted to track neural lineages and study gene functions upon tamoxifen (TAM) administration. We have observed that prenatal TAM treatment caused high rates of delayed delivery and fetal mortality. This substance could produce undesired results, leading to data misinterpretation. Here, we report that administration of TAM during early stages of cortical neurogenesis promoted precocious neural differentiation, while it inhibited neural progenitor cell (NPC) proliferation. The TAM-induced inhibition of NPC proliferation led to deficits in cortical neurogenesis, dendritic morphogenesis, synaptic formation, and cortical patterning in neonatal and postnatal offspring. Mechanistically, by employing single-cell RNA-sequencing (scRNA-seq) analysis combined with in vivo and in vitro assays, we show TAM could exert these drastic effects mainly through dysregulating the Wnt-Dmrta2 signaling pathway. In adult mice, administration of TAM significantly attenuated NPC proliferation in both the subventricular zone and the dentate gyrus. This study revealed the cellular and molecular mechanisms for the adverse effects of TAM on corticogenesis, suggesting that care must be taken when using the TAM-induced CreER/LoxP system for neural lineage tracing and genetic manipulation studies in both embryonic and adult brains.

show abstract

mentioning

confidence: 99%

Single-cell RNA-seq analysis revealed long-lasting adverse effects of tamoxifen on neurogenesis in prenatal and adult brains

Lee

Zhou

Liu

et al. 2020

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…With respect to growth, the infant had been small of built but had caught up in her growth curve by the age of 2 years. Follow-up reports about infants exposed to tamoxifen in utero are scarce; however, Koca et al described a healthy 2-year-old child exposed to tamoxifen in the fetus for 1.5 months [ 5 ]. Ishizuka and Satou described the normal development up to 5 years follow-up of the infant exposed to tamoxifen during the first trimester.…”

Section: Discussionmentioning

confidence: 99%

A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen

Okada

Hitaka

Kido

et al. 2020

Case Reports in Pediatrics

View full text Add to dashboard Cite

Tamoxifen, an estrogen receptor antagonist, is contraindicated in pregnant women due to its teratogenic activity. In the present study, we report the case of an infant whose mother received tamoxifen for breast cancer while unaware of the pregnancy. The infant, born at 29 weeks and 6 days of gestational age with a birth weight of 1664 g, had no congenital anomalies. This case presents detailed information on the development of an infant with placental transfer of tamoxifen. The infant has grown and developed normally throughout a 5-year follow-up period, but long-term vigilance continues.

show abstract

“…A case report of juvenile breast hypertrophy revealed some benefit from treatment with tamoxifen [37]. However, tamoxifen should be avoided in pregnancy due to case reports of teratogenicity [38][39][40][41][42] and cumulative increased venous thromboembolism risk. It should be noted that while cessation of lactation was recommended and able to be achieved for the patient in this case report, this may be challenging or not universally plausible for patients in lowresource settings in which formula may not be available.…”

Section: Discontinuing Milk Productionmentioning

confidence: 99%

Gestational Gigantomastia: Case Report and Review of Treatment Options

2024

Ann Case Report

View full text Add to dashboard Cite

Gestational gigantomastia is a rare and devastating condition involving rapid and excessive enlargement of the breast tissue during pregnancy or postpartum. We review the workup, assessment, and care of a patient with gestational gigantomastia with superimposed mastitis. Conservative treatment, medical management, and surgical options should be explored with patients. It is also important for providers to be cognizant of the psychological impact of this condition.

show abstract

Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature

Cited by 14 publications

References 6 publications

Single-cell RNA-seq analysis revealed long-lasting adverse effects of tamoxifen on neurogenesis in prenatal and adult brains

Single-cell RNA-seq analysis revealed long-lasting adverse effects of tamoxifen on neurogenesis in prenatal and adult brains

A Follow-Up Report of an Infant Born to a Mother Receiving Tamoxifen

Gestational Gigantomastia: Case Report and Review of Treatment Options

Contact Info

Product

Resources

About